TEVA Teva Pharmaceutical Industries Ltd
- Stocks
- Healthcare
- NYSE: TEVA
Price (delayed)
$16.37
Market cap
$18.78B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.14
Enterprise value
$34.14B
Highlights
TEVA's net income has surged by 88% since the previous quarter and by 65% year-on-year
Teva Pharmaceutical Industries's EPS has surged by 88% QoQ and by 65% YoY
The debt has declined by 7% year-on-year but it has increased by 3.4% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Key stats
What are the main financial stats of TEVA
Market
Valuations
Earnings
Shares outstanding
1.15B
Market cap
$18.78B
Enterprise value
$34.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.75
Price to sales (P/S)
1.13
EV/EBIT
37.85
EV/EBITDA
17.74
EV/Sales
2.05
Revenue
$16.63B
Gross profit
$8.25B
Operating income
$894M
Net income
-$158M
EBIT
$902M
EBITDA
$1.93B
Free cash flow
$890M
Per share
Balance sheet
Liquidity
EPS
-$0.14
EPS diluted
-$0.16
Free cash flow per share
$0.78
Book value per share
$5.95
Revenue per share
$14.5
TBVPS
$17.47
Total assets
$40.13B
Total liabilities
$33.3B
Debt
$17.52B
Equity
$6.83B
Working capital
$759M
Debt to equity
2.57
Current ratio
1.06
Quick ratio
0.48
Net debt/EBITDA
7.98
Margins
Efficiency
Dividend
EBITDA margin
11.6%
Gross margin
49.6%
Net margin
-1%
Operating margin
5.4%
Return on assets
-0.4%
Return on equity
-2.6%
Return on invested capital
4%
Return on capital employed
3.2%
Return on sales
5.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TEVA stock price
How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
0.49%
1 week
6.44%
1 month
-1.56%
1 year
-4.6%
YTD
-25.73%
QTD
-2.33%
Financial performance
How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.63B
Gross profit
$8.25B
Operating income
$894M
Net income
-$158M
Gross margin
49.6%
Net margin
-1%
TEVA's operating income has soared by 109% from the previous quarter and by 3.7% YoY
The operating margin has soared by 108% QoQ
TEVA's net income has surged by 88% since the previous quarter and by 65% year-on-year
The net margin has surged by 87% since the previous quarter and by 64% year-on-year
Price vs fundamentals
How does TEVA's price correlate with its fundamentals
Growth
What is Teva Pharmaceutical Industries's growth rate over time
Valuation
What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
2.75
P/S
1.13
EV/EBIT
37.85
EV/EBITDA
17.74
EV/Sales
2.05
Teva Pharmaceutical Industries's EPS has surged by 88% QoQ and by 65% YoY
TEVA's price to book (P/B) is 62% higher than its 5-year quarterly average of 1.7 but 19% lower than its last 4 quarters average of 3.4
Teva Pharmaceutical Industries's equity has increased by 9% QoQ and by 7% YoY
The P/S is 41% above the 5-year quarterly average of 0.8 but 6% below the last 4 quarters average of 1.2
TEVA's revenue is up by 2.1% year-on-year
Efficiency
How efficient is Teva Pharmaceutical Industries business performance
Teva Pharmaceutical Industries's return on sales has surged by 93% QoQ but it has decreased by 25% YoY
The company's return on invested capital has surged by 90% QoQ but it fell by 15% YoY
Teva Pharmaceutical Industries's return on assets has surged by 88% QoQ and by 64% YoY
TEVA's ROE has soared by 88% from the previous quarter and by 60% YoY
Dividends
What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Teva Pharmaceutical Industries financials performed over time
The total assets is 21% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has increased by 19% YoY and by 2.9% QoQ
The total assets is up by 4.5% since the previous quarter but it is down by 2.9% year-on-year
The debt is 157% greater than the equity
TEVA's debt to equity is down by 14% YoY and by 5% from the previous quarter
Teva Pharmaceutical Industries's equity has increased by 9% QoQ and by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.